Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W M Johnson

Showing results (171-180 of 218) with videos related to

Pageof 22
Sort By:
Blood|December 17, 2008
Phase 1/2 study of fractionated (131)I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapyTim M Illidge, Mike Bayne, Nicholas S Brown, et al.
Blood Advances|January 15, 2020
Maximum tumor diameter is associated with event-free survival in PET-negative patients with stage I/IIA Hodgkin lymphomaTim M Illidge, Elizabeth H Phillips, Nicholas Counsell, et al.
Oncogene|August 7, 2003
The nuclear BAG-1 isoform, BAG-1L, enhances oestrogen-dependent transcriptionRamsey I Cutress, Paul A Townsend, Adam Sharp, et al.
British Journal of Haematology|May 10, 2017
Prognostic models for primary mediastinal (thymic) B-cell lymphoma derived from 18-FDG PET/CT quantitative parameters in the International Extranodal Lymphoma Study Group (IELSG) 26 studyLuca Ceriani, Maurizio Martelli, Annarita Conconi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 30, 2005
Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519)Peter W M Johnson, John A Radford, Michael H Cullen, et al.
Scientific Reports|May 24, 2022
Prognostic significance of crown-like structures to trastuzumab response in patients with primary invasive HER2 + breast carcinomaCharles N Birts, Constantinos Savva, Stéphanie A Laversin, et al.
The Lancet. Oncology|September 18, 2018
Determinants of ovarian function after response-adapted therapy in patients with advanced Hodgkin's lymphoma (RATHL): a secondary analysis of a randomised phase 3 trialRichard A Anderson, Rachel Remedios, Amy A Kirkwood, et al.
Oncogene|August 23, 2006
Pharmacological inhibitors of NF-kappaB accelerate apoptosis in chronic lymphocytic leukaemia cellsB M Pickering, S de Mel, M Lee, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 29, 2022
KIR2DS2 Expression Identifies NK Cells With Enhanced Anticancer ActivityMatthew D Blunt, Andres Vallejo Pulido, Jack G Fisher, et al.
Trials|November 11, 2018
RIVA - a phase IIa study of rituximab and varlilumab in relapsed or refractory B-cell malignancies: study protocol for a randomized controlled trialSean H Lim, Kim M Linton, Graham P Collins, et al.
Pageof 22

Showing results (171-180 of 218) with videos related to

Sort By:
Pageof 22
Blood|December 17, 2008
Phase 1/2 study of fractionated (131)I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapyTim M Illidge, Mike Bayne, Nicholas S Brown, et al.
Blood Advances|January 15, 2020
Maximum tumor diameter is associated with event-free survival in PET-negative patients with stage I/IIA Hodgkin lymphomaTim M Illidge, Elizabeth H Phillips, Nicholas Counsell, et al.
Oncogene|August 7, 2003
The nuclear BAG-1 isoform, BAG-1L, enhances oestrogen-dependent transcriptionRamsey I Cutress, Paul A Townsend, Adam Sharp, et al.
British Journal of Haematology|May 10, 2017
Prognostic models for primary mediastinal (thymic) B-cell lymphoma derived from 18-FDG PET/CT quantitative parameters in the International Extranodal Lymphoma Study Group (IELSG) 26 studyLuca Ceriani, Maurizio Martelli, Annarita Conconi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 30, 2005
Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519)Peter W M Johnson, John A Radford, Michael H Cullen, et al.
Scientific Reports|May 24, 2022
Prognostic significance of crown-like structures to trastuzumab response in patients with primary invasive HER2 + breast carcinomaCharles N Birts, Constantinos Savva, Stéphanie A Laversin, et al.
The Lancet. Oncology|September 18, 2018
Determinants of ovarian function after response-adapted therapy in patients with advanced Hodgkin's lymphoma (RATHL): a secondary analysis of a randomised phase 3 trialRichard A Anderson, Rachel Remedios, Amy A Kirkwood, et al.
Oncogene|August 23, 2006
Pharmacological inhibitors of NF-kappaB accelerate apoptosis in chronic lymphocytic leukaemia cellsB M Pickering, S de Mel, M Lee, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 29, 2022
KIR2DS2 Expression Identifies NK Cells With Enhanced Anticancer ActivityMatthew D Blunt, Andres Vallejo Pulido, Jack G Fisher, et al.
Trials|November 11, 2018
RIVA - a phase IIa study of rituximab and varlilumab in relapsed or refractory B-cell malignancies: study protocol for a randomized controlled trialSean H Lim, Kim M Linton, Graham P Collins, et al.
Pageof 22